Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nicotinic Acetylcholine Receptor Alpha6 Beta2 (α6β2 nAChR)
- Target
- α6β2 nAChR
- Molecular classification
- Receptor, Ion channel, Ligand-gated ion channel, Cys-loop receptor
01
Overview
The nicotinic acetylcholine receptor alpha6 beta2 (α6β2 nAChR) is a specific subtype of nicotinic acetylcholine receptors that plays a crucial role in neuronal signaling, particularly in dopaminergic pathways. This receptor is a pentameric protein complex composed of α6 and β2 subunits, functioning as a ligand-gated ion channel. It is primarily expressed in dopamine-releasing neurons in the midbrain and dominates nicotinic receptor function in the nucleus accumbens. The α6β2 nAChR is involved in mediating fast synaptic transmission, modulating dopamine release, and contributing to the reinforcing and addictive effects of nicotine. It is a therapeutic target for nicotine addiction, alcohol addiction, and Parkinson's disease.
- Other names
- α6β2 Nicotinic Receptorα6β2 nAChR
02
Mechanism of action
Ligand-gated ion channel activation/inhibition; Modulation of dopamine release
03
Biological functions
NeurotransmissionDopamine regulationIon channel activitySynaptic transmission
04
Disease associations
Nicotine addictionAlcohol addictionParkinson's disease
05
Safety considerations
Potential for off-target effects with non-selective ligandsDevelopment of resistanceSide effects related to dopamine modulation
06
Interacting drugs
Acetylcholine
4 more in the full profile.
Beyond the preview
Go deeper on Nicotinic Acetylcholine Receptor Alpha6 Beta2 (α6β2 nAChR).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nicotinic Acetylcholine Receptor Alpha6 Beta2 (α6β2 nAChR).